(Q35019662)

5 August 2017

1 reference

title

DNA-based drug interactions of cisplatin (English)

1 reference

5 August 2017

1 reference

Crul M

1

1 reference

5 August 2017

van Waardenburg RC

series ordinal

2

1 reference

5 August 2017

Beijnen JH

series ordinal

3

1 reference

5 August 2017

Schellens JH

series ordinal

4

1 reference

5 August 2017

publication date

1 December 2002

1 reference

5 August 2017

published in

Cancer Treatment Reviews

1 reference

5 August 2017

volume

28

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

291-303

1 reference

Drugs five years later. Cisplatin

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Cellular accumulation of the anticancer agent cisplatin: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Cisplatin and DNA repair in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Reaction mechanism of human DNA repair excision nuclease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

1 reference

7 January 2021

Relationships between DNA repair and transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Cisplatin resistance and DNA repair

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Fluorouracil: biochemistry and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Effects of cis-diamminedichloroplatinum on DNA incorporation and cytotoxicity of 1-beta-D-arabinofuranosylcytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Evaluation of synergism of drugs cis-mdiamminedichloroplatinum (II) and arabinosylcytosine on the level of chemical interaction with DNA and on the growth of mouse leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Cellular efflux pump and interaction between cisplatin and paclitaxel in ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Effects of CPT-11 in combination with other anti-cancer agents in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Inhibition of cis‐diamminedichloroplatinum (II)‐induced DNA interstrand cross‐link removal by 7‐ethyl‐10‐hydroxy‐camptothecin in HST‐1 human squamous‐carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

DNA topoisomerases as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2802%2900093-2

7 January 2021

10.1016/S0305-7372(02)00093-2

Identifiers

DOI

1 reference

5 August 2017

1 reference